The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ApexOnco Front Page
Recent articles
BeOne's degrader BG-60366 appears to have been discontinued.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.